KOA

4 stories · following the connections

Business

Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial

By Nasdaq OMXMar 16, 2018, 11:00 AM UTC

Business

Cellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis

By Nasdaq OMXDec 9, 2016, 1:00 PM UTC

Business

Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy

By Nasdaq OMXJan 13, 2016, 1:00 PM UTC

Business

Cellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis

By Nasdaq OMXJan 6, 2016, 2:04 PM UTC